▎药明康德内容团队编辑（来源：北京大学生物医学前沿创新中心）三阴性乳腺癌（TNBC）是恶性程度最高的乳腺癌亚型，由于缺乏雌激素受体（ER）、孕激素受体（PR）以及人表皮生长因子受体2（HER2）的表达，这类乳腺癌患者无法从激素治疗或HER2靶向治疗中 ...

研究人员从常见的姜、蒜、芦荟和柠檬中提取出了植物源纳米颗粒（PNP），并发现其包含Nano10和ELN两种不同类型。体外和体内实验均表明，PNP能够被肠道细菌摄取。在众多的肠道细菌中，Lachnospiraceae、Bacteroidaceae等细菌家族在摄取PNP的过程中表现得尤为活跃，是主要的摄取菌。而且，PNP的摄取效率并非一成不变，它会受到PNP类型、植物来源以及肠道微环境等多种因素的影响 ...

Anti-PD-1 and anti-PD-L1 antibodies have resulted in long-term responses with minimal side effects in significant numbers of patients with melanoma, lung, kidney, bladder and triple-negative ...

而癌细胞表面表达的PD-L1，当然是制约抗肿瘤免疫应答的敌人，所以帮助PD-L1存在的“敌人的朋友”，当然也要打击才行。 近日，西安交通大学李磊 ...

Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at ...

In combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) ...

Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 ...

Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) ...

Researchers reveal that gut microbiota influence the effectiveness of immune checkpoint inhibitors (ICIs) in cancer treatment ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...